程序性死亡受体 1：癌症免疫治疗 100 多年后的治疗成功。
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.
机构信息
Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/.
出版信息
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8. doi: 10.1002/anie.201307906. Epub 2014 Jan 28.
Abstract
No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.
摘要
没有其他癌症治疗靶点类像程序性死亡受体 1（PD-1）途径那样令人兴奋。抗 PD-1 和 PD-1 配体的抗体代表了治疗上的突破，是广泛有效和持久的癌症免疫疗法的首例。癌症首次似乎从一种通常无法治愈的疾病转变为一种“临床可管理”的疾病。
相似文献
1
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.程序性死亡受体 1：癌症免疫治疗 100 多年后的治疗成功。
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8. doi: 10.1002/anie.201307906. Epub 2014 Jan 28.
2
Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?免疫检查点 PD-1/PD-L1：抗体之外是否还有其他可能？
Angew Chem Int Ed Engl. 2018 Apr 23;57(18):4840-4848. doi: 10.1002/anie.201710407. Epub 2018 Feb 23.
3
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.PD-Loma：一种具有对 PD-1/PD-L1 通路阻断共同敏感性的癌症实体。
Br J Cancer. 2019 Jan;120(1):3-5. doi: 10.1038/s41416-018-0294-4. Epub 2018 Nov 9.
4
The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.程序性细胞死亡蛋白1（PD-1）及其配体在儿童癌症中的作用。
Pediatr Blood Cancer. 2015 Feb;62(2):190-197. doi: 10.1002/pbc.25284. Epub 2014 Oct 18.
5
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.PD-1 和 PD-L1 在癌症免疫治疗中的作用：临床意义和未来思考。
Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19.
6
Hiding in Plain Sight: Soluble Immunomodulatory Receptors.藏而不露：可溶性免疫调节受体。
Trends Immunol. 2018 Oct;39(10):771-774. doi: 10.1016/j.it.2018.08.004. Epub 2018 Sep 5.
7
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.癌症免疫治疗中 PD-1 和 PD-L1 抗体的临床应用最新进展。
J Hematol Oncol. 2017 Dec 1;10(1):174. doi: 10.1186/s13045-017-0541-9.
8
Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.新型程序性细胞死亡 (PD)-1 和其配体 PD-L1 小分子抑制剂在癌症免疫治疗中的应用：专利文献的综述更新。
Recent Pat Anticancer Drug Discov. 2019;14(2):100-112. doi: 10.2174/1574892813666181029142812.
9
Part I: Checkpoint inhibitors in cancer therapy.第一部分：癌症治疗中的检查点抑制剂。
Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051.
10
Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.调控肠道菌群：增强 PD-1 和 PD-L1 阻断治疗疗效的新策略。
Front Immunol. 2018 Mar 5;9:374. doi: 10.3389/fimmu.2018.00374. eCollection 2018.
引用本文的文献
1
Nonsymmetrically Substituted 1,1'-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction.非对称取代的基于1,1'-联苯的PD-1/PD-L1相互作用小分子抑制剂
ACS Med Chem Lett. 2024 Jun 3;15(6):828-836. doi: 10.1021/acsmedchemlett.4c00042. eCollection 2024 Jun 13.
2
Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and characterisation.新型 PD-1/PD-L1 小分子抑制剂的鉴定：虚拟筛选、合成与表征。
J Enzyme Inhib Med Chem. 2024 Dec;39(1):2353711. doi: 10.1080/14756366.2024.2353711. Epub 2024 Jun 17.
3
1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists.作为PD-1/PD-L1拮抗剂的1,5-二取代四唑
RSC Med Chem. 2024 Feb 21;15(4):1210-1215. doi: 10.1039/d3md00746d. eCollection 2024 Apr 24.
4
Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.蛋白酪氨酸磷酸酶SHP2抑制剂发现方面的最新进展。
RSC Med Chem. 2022 Jan 15;13(3):246-257. doi: 10.1039/d1md00386k. eCollection 2022 Mar 23.
5
Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint.利用PD-L1界面肽进行PD-1免疫检查点的正电子发射断层扫描成像。
RSC Chem Biol. 2020 Aug 27;1(4):214-224. doi: 10.1039/d0cb00070a. eCollection 2020 Oct 1.
6
Supramolecular agents for combination of photodynamic therapy and other treatments.用于光动力疗法与其他治疗相结合的超分子制剂。
Chem Sci. 2021 May 10;12(21):7248-7268. doi: 10.1039/d1sc01125a.
7
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.免疫检查点抑制剂联合血管生成抑制剂治疗晚期非小细胞肺癌。
Front Immunol. 2021 Jun 2;12:689132. doi: 10.3389/fimmu.2021.689132. eCollection 2021.
8
Human iPS Cells Loaded with MnO-Based Nanoprobes for Photodynamic and Simultaneous Enhanced Immunotherapy Against Cancer.负载基于MnO的纳米探针的人诱导多能干细胞用于光动力和同步增强癌症免疫治疗
Nanomicro Lett. 2020 Jun 16;12(1):127. doi: 10.1007/s40820-020-00452-y.
9
Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists.作为PD-1/PD-L1拮抗剂的咪唑并吡啶的设计、合成及生物学评价
ACS Med Chem Lett. 2021 Apr 28;12(5):768-773. doi: 10.1021/acsmedchemlett.1c00033. eCollection 2021 May 13.
10
Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.通过分子动力学模拟探索含Src同源2结构域蛋白酪氨酸磷酸酶2（SHP2）的变构机制
Front Chem. 2020 Nov 23;8:597495. doi: 10.3389/fchem.2020.597495. eCollection 2020.
本文引用的文献
1
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.年度药物：程序性死亡受体 1/程序性死亡受体配体 1 受体单克隆抗体。
Eur J Cancer. 2013 Sep;49(14):2968-71. doi: 10.1016/j.ejca.2013.07.001. Epub 2013 Jul 29.
2
New checkpoint inhibitors ride the immunotherapy tsunami.新型检查点抑制剂搭乘免疫疗法的浪潮。
Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066.
3
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
4
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.拉罗替尼（anti-PD-1）治疗黑色素瘤的安全性和肿瘤应答。
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.
5
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.抗程序性死亡-1 和抗程序性死亡配体 1 抗体在癌症治疗中的应用。
Expert Opin Biol Ther. 2013 Jun;13(6):847-61. doi: 10.1517/14712598.2013.770836. Epub 2013 Feb 19.
6
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
7
New drugs in melanoma: it's a whole new world.新型黑色素瘤药物：全新世界。
Eur J Cancer. 2011 Sep;47(14):2150-7. doi: 10.1016/j.ejca.2011.06.052. Epub 2011 Jul 27.
8
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.RAF 抑制剂的临床疗效需要在 BRAF 突变型黑色素瘤中广泛的靶标阻断。
Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.
9
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.抗CD28单克隆抗体TGN1412 1期试验中的细胞因子风暴
N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.
10
The hybridoma revolution: an offshoot of basic research.杂交瘤革命：基础研究的一个分支。
Bioessays. 1999 Nov;21(11):966-73. doi: 10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z.
Zotero 插件